All News
COAST-V and COAST-X trial results: Both TNFi experienced and naive AS pts had better work productivity compared to PBO. #EULAR2020 @RheumNow poster #THU0396
https://t.co/UPDpLqCSkG https://t.co/UTLzxxTG8K
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
SEC shows improvement in both tender and swollen peripheral joints in AS pts. #EULAR2020 @RheumNow poster #THU0397
https://t.co/M0D6Ruh8ta https://t.co/kuShSUhXbf
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
Thoughts on the #EULAR2020 e-congress? As a life long learner, I’ve enjoyed being able to attend but I miss my interactions with colleagues @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
Interesting abstract #ABO113, out of Germany found that H. Pylori ab p66-UreB, p29-UreA, and p54-flagelin are more prominent in PsA/PsO pts. Another suggested potential link to the gut microbiome and dz? Hopefully, more data to come. #EULAR2020 @RheumNow https://t.co/mQRhsmgsHw
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
This UK study to determine neutrophil function in PsA found that SEC does not affect neutrophil host defense. Check out #ABO115 for further details. An interesting find w/ regard to the inflammatory blockade and mediators of dz. #EULAR2020 @RheumNow https://t.co/EwLdlKU06A
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
IL-36 as a new biomarker/tx target in SpA? Check out this interesting in vitro study out of the UK and the IL-36 upstream induction of the IL-17/IL-23 pathway. #EULAR2020 @RheumNow #SAT0356 https://t.co/YTVepexd45
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
Spanish COSPAR registry results reveal changes in axSpA pt gut microbiota which are associated with radiographic damage, disease activity, affectation of enthesis and axial mobility. #SAT0362 https://t.co/goo4Qkaqdb #EULAR2020 @RheumNow
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
10 ReA pt study out of India reviewing ETN-b found that all pts (previously on ETN) responded to biosimilar med without new safety signals. Further details are here on abstract #AB0632 https://t.co/lRA2IDvU4H #EULAR2020 @RheumNow https://t.co/QyhwBzBBH3
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
In regard to biosimilars, what has your experience been? #EULAR2020 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
What do you think of #EULAR2020goesvirtual compared to an in person #EULAR? @eular_org @RheumNow @CRASCRRheum #EULAR2020goesvirtual
Janet Pope Janetbirdope ( View Tweet)
#EULAR2020 Friday afternoon command station with my co-worker/health and wellness coach. @KDAO2011 your set up is much better! @RheumNow #bedrest https://t.co/Ldow1eemLZ
Dr. Rachel Tate uptoTate ( View Tweet)
Another study shows that US guided SIJs in axSpA pts are safe and effective. Abstract #AB0642. #EULAR2020 @RheumNow https://t.co/KMPioCKr0n
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
“Let’s consider treating nr-ax SpA and axSpA as serious, similar entities for better treatment options for our patients.” Dr. D. Poddubnyy discussing EXCEED study results and extrapolation of data. #EULAR2020 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
Interesting observation: obese patients seem to respond better to etanercept than to mAb TNFi @RheumNow https://t.co/WrjwE4jUNI
k dao KDAO2011 ( View Tweet)
#eular2020 #op0226 humanized antiIL17a ab NETAKIMAB (NTK)for PsA Ph3 PATERA trial: pts who failed cDMARDs and/or 1TNFi experience significantly ⬆️ ACR20/50/70 &PsACR response vs PBO. DAPSA remission 36.08% NTK vs 13.4%PBO. AEs: lympho&neutropenia, ⬆️cholesterol,⬆️bili @RheumNow https://t.co/xqc9Z1T9O0
Olga Petryna DrPetryna ( View Tweet)
I have been impressed with the quality and content of the presentations at #EULAR2020! Here I am trying to navigate the meeting in between telehealth visits at my command center! @RheumNow https://t.co/aGDAr8PPkA
k dao KDAO2011 ( View Tweet)
Big one from plenary, new option in ANCA-associated vasculitis:
avacopan (anti-C5a) vs prednisolone in patients receiving CYC/RTX: non-inf at 26w, superior at 52w in the phase III ADVOCATE trial with reduction in steroid toxicity
Merkel, Jayne et al OP0011 #EULAR2020 @RheumNow
David Liew drdavidliew ( View Tweet)
#eular2020 #op0302 Ianalumab (VAY736) dual action BAFFreceptor inhibitor/B cell depletion meets primary end point in p2b for pSS: EESDAI⬇️1.92 pts over PBO at wk24. Dis not meet 2ry endpoint ESSPRI&FACIT-F. Good side effect profile w/mild inj site reactions mostly @RheumNow https://t.co/9qsfUNho9h
Olga Petryna DrPetryna ( View Tweet)
You might think that steroid exposure in PMR patients wouldn't lead to new comorbidities.
These data beg to differ. New steroid-related comorbidities ++ across domains vs matched controls in real-world US claims data.
We need steroid-sparing in PMR.
OP0271 #EULAR2020 @RheumNow https://t.co/mSzWcJSpfV
David Liew drdavidliew ( View Tweet)
New #therapeutic strategies in #SLE management
#EULAR2020 https://t.co/dhvTKd4EGB
dr hanady manasfi hanadymanasfi ( View Tweet)